Research programme: bradykinin B1 receptor antagonists - Amgen
Latest Information Update: 01 Sep 2011
At a glance
- Originator Amgen
- Class Amides; Naphthalenes; Piperazines; Pyrazines; Small molecules; Sulfonamides; Sulfones
- Mechanism of Action Bradykinin B1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Inflammation; Pain